Literature DB >> 27745866

Cystatin-C and TGF-β levels in patients with diabetic nephropathy.

Mumtaz Takir1, Aslı Dogruk Unal2, Osman Kostek3, Nilufer Bayraktar2, Nilgun Guvener Demirag2.   

Abstract

OBJECTIVE: To evaluate renal impairment in type 2 diabetic patients with normoalbuminuria or microalbuminuria by detection of serum cystatin C and serum and urinary TGF-β levels.
METHODS: Cross-sectional study conducted at the Department of Endocrinology in Baskent University School of Medicine. Patients with type 2 diabetes mellitus without known overt diabetic nephropathy were included in the study. Recruited patients were stratified into four groups, matched in terms of age, gender, microalbuminuria level and estimated GFR calculated with MDRD.
RESULTS: 78 patients were enrolled. They were categorized into four groups depending on their urinary albumin excretion and estimated glomerular filtration rate. Macrovascular complication was found to be higher in patients with microalbuminuria than in other patients (p<0.01), but there were no differences in terms of other diabetic complications. Serum cystatin C level was significantly higher in normoalbuminuric group one patients, while serum and urinary TGF-β1 levels were higher in microalbuminuric group two patients. The serum level of cystatin C was found to negatively correlate with eGFR in group two patients (r=-0.892, p<0.001). Finally, there was a negative correlation between eGFR and cystatin C in all the patient groups (r=-0.726, p=0.001).
CONCLUSIONS: Although urinary albumin excretion is recommended for the detection of type two diabetic nephropathy, there is a group of patients with decreased eGFR but without increased urinary albumin excretion, in which serum cystatin C level was indicated to be used as an early biomarker of diabetic nephropathy. Copyright Â
© 2016. Published by Elsevier España, S.L.U.

Entities:  

Keywords:  Cistatina C; Cystatin C; Diabetic nephropathy; Microalbuminuria; Nefropatía diabética; Normoalbuminuria; TGF-β1

Mesh:

Substances:

Year:  2016        PMID: 27745866     DOI: 10.1016/j.nefro.2016.06.011

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  6 in total

Review 1.  Novel biomarkers for prognosticating diabetic kidney disease progression.

Authors:  Shilna Muttickal Swaminathan; Indu Ramachandra Rao; Srinivas Vinayak Shenoy; Attur Ravindra Prabhu; Pooja Basthi Mohan; Dharshan Rangaswamy; Mohan V Bhojaraja; Shivashankara Kaniyoor Nagri; Shankar Prasad Nagaraju
Journal:  Int Urol Nephrol       Date:  2022-10-22       Impact factor: 2.266

2.  Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-ß1).

Authors:  Felipe Cabezas; Pamela Farfán; María-Paz Marzolo
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

3.  Diagnostic Accuracy of Serum Cystatin C for Early Recognition of Nephropathy in Type 2 Diabetes Mellitus.

Authors:  Suman Sapkota; Saroj Khatiwada; Shrijana Shrestha; Nirmal Baral; Robin Maskey; Shankar Majhi; Lal Chandra; Madhab Lamsal
Journal:  Int J Nephrol       Date:  2021-04-26

Review 4.  Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature.

Authors:  Sopida Thipsawat
Journal:  Diab Vasc Dis Res       Date:  2021 Nov-Dec       Impact factor: 3.291

5.  Therapeutic effect and mechanism of combination therapy with ursolic acid and insulin on diabetic nephropathy in a type I diabetic rat model.

Authors:  Yang Liu; Jin-Yan Zheng; Zhi-Tao Wei; Shu-Kun Liu; Ji-Lei Sun; Yin-Hui Mao; Yong-De Xu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

6.  Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide.

Authors:  Xuebing Zhang; Pei Liu; Zhen Zhang
Journal:  Clinics (Sao Paulo)       Date:  2020-11-11       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.